article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

Klaus Wagenbauer, PhD, Founder & CEO, Plectonic, on: ‘Programmable DNA-origami-based T cell engagers: PTE’. Damian Trojanowski, Dr, R&D Specialist, Antibody Discovery Group, Pure Biologics, on: ‘Anti-GARP/TGFb1 antibodies in new twist – multifunctional shapers of anti-tumour immunity’.